Halozyme Therapeutics Inc (NASDAQ:HALO) has a beta value of 1.19 and has seen 3.1 million shares traded in the last trading session. The company, currently valued at $6.57B, closed the last trade at $53.31 per share which meant it lost -$2.33 on the day or -4.19% during that session. The HALO stock price is -32.25% off its 52-week high price of $70.50 and 21.2% above the 52-week low of $42.01.
The consensus among analysts is that Halozyme Therapeutics Inc (HALO) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.
Halozyme Therapeutics Inc (NASDAQ:HALO) trade information
Over the past 30 days, the shares of Halozyme Therapeutics Inc (NASDAQ:HALO) have changed -12.88%.
Wall Street analysts have a consensus price target for the stock at $62, which means that the shares’ value could jump 14.02% from current levels. The projected low price target is $62.0 while the price target rests at a high of $62.0. In that case, then, we find that the current price level is -16.3% off the targeted high while a plunge would see the stock gain -16.3% from current levels.
Halozyme Therapeutics Inc (HALO) estimates and forecasts
The company’s shares have gained 9.99% over the past 6 months.
Earnings growth for 2025 is a modest 26.57% while over the next 5 years, the company’s earnings are expected to increase by 28.69%.
HALO Dividends
Halozyme Therapeutics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Halozyme Therapeutics Inc (NASDAQ:HALO)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 17.62 million shares worth more than $922.58 million. As of 2024-06-30, BLACKROCK INC. held 13.8613% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 12.88 million shares as of 2024-06-30. The firm’s total holdings are worth over $674.47 million and represent 10.1336% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Apr 30, 2025 , the former fund manager holds about 3.34% shares in the company for having 4.12 shares of worth $219.6 million while later fund manager owns 3.89 shares of worth $207.5 million as of Mar 31, 2025 , which makes it owner of about 3.16% of company’s outstanding stock.
